Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs.
服用 GLP-1 和雙重 GIP/GLP-1 受體激動劑患者的飲食攝取:敘述性回顧及研究需求討論。
Obes Pillars 2024-08-23
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.
GLP-1激動劑在肥胖症中的新興角色:隨機對照試驗的全面回顧。
Int J Mol Sci 2023-07-18
Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review.
糖尿病患者體重減輕的系統性回顧:葡萄糖樣肽-1受體激動劑的作用。
Cureus 2023-07-18
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists.
肥胖症和第二型糖尿病藥物治療的新發展 - GLP-1 受體激動劑的範疇內和範疇外。
Biomedicines 2024-06-27
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.
GLP-1 及雙重 GIP/GLP-1 受體激動劑的作用機制與治療應用。
Front Endocrinol (Lausanne) 2024-08-08
Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists.
能量平衡與肥胖:胰高血糖素樣肽-1 受體激動劑的新興角色。
Curr Opin Clin Nutr Metab Care 2024-08-16
Efficacy of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Weight Loss Management in Non-Diabetic Patients.
非糖尿病患者使用胰高血糖素樣肽-1 (GLP-1) 受體激動劑進行減重管理的療效。
Cureus 2024-08-21
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.
GLP-1 單一、雙重及三重受體激動劑在治療第二型糖尿病和肥胖症中的應用:敘述性回顧。
EClinicalMedicine 2024-09-16
Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks.
針對肥胖的胰高血糖素樣受體-1激動劑:體重減輕結果、耐受性、副作用及風險。
Obes Pillars 2024-09-17